Japan Chemical Daily

Japan's leading chemical industry newspaper

Log In

Daiichi Sankyo Partners With US Firm to Enter Cancer Cell Therapy Market

Filed Under: Pharma Tagged With: , , , , ,

Daiichi Sankyo Co. Ltd. (TYO:4568) is entering Japan’s market for anti-cancer cell therapy drugs in partnership with U.S.-based Kite Pharma…...

Please subscribe to read the full story.

Subscribe Free Trial

Related Articles:

AGC in Race to Bolster CDMO Operations Across US, Europe and Japan
AGC in Race to Bolster CDMO Operations Across US, Europe and…
AGC Looks to Advance Into Gene and Cell Therapy Business With Tender Offer for MolMed
AGC Looks to Advance Into Gene and Cell Therapy Business…
Spate of Japanese-Developed COVID-19 Vaccines Head Into Later Stages of Development, Clinical Trials
Spate of Japanese-Developed COVID-19 Vaccines Head Into…
Japan’s Leading Drug Manufacturers Grow Sales Revenue on Back of Mainstay Products
Japan’s Leading Drug Manufacturers Grow Sales Revenue on…
Raw Material Shortages Create Difficulties in Biopharma Production
Raw Material Shortages Create Difficulties in Biopharma…
Kyoto University Venture Thyas Uses iPS Cells to Generate Killer T Cells for Cancer Treatment
Kyoto University Venture Thyas Uses iPS Cells to Generate…